Erin Himes
Family · Plymouth Meeting, PANPI 1538946991
Payments from drug & device makers
Across 10 payments — averaging $28.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$138
- Otsuka America Pharmaceutical, Inc.$49
- Teva Pharmaceuticals USA, Inc.$44
- Takeda Pharmaceuticals U.S.A., Inc.$34
- Sumitomo Pharma America, Inc.$23
What the payments were for
- Food & beverage$289100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 5 | $138 |
| Otsuka America Pharmaceutical, Inc. | 2 | $49 |
| Teva Pharmaceuticals USA, Inc. | 1 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $34 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
How this compares
$289 in reported general payments places this provider in the 45th percentile of 4,717 family providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 86 | $49,823 |
| MyrbetriqMirabegron | 34 | $15,379 |
| EntrestoSacubitril/Valsartan | 15 | $9,534 |
| JardianceEmpagliflozin | 11 | $6,269 |
| Potassium Chloride | 134 | $4,807 |
| NuedextaDextromethorphan Hbr/Quinidine | 11 | $4,096 |
| Autoshield Duo Pen NeedlePen Needle,dual Safety,diabetc | 29 | $2,918 |
| TradjentaLinagliptin | 21 | $2,848 |
| Ezetimibe | 47 | $2,559 |
| Memantine Hcl | 48 | $2,404 |
| Atorvastatin Calcium | 177 | $2,355 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 13 | $2,282 |
| Pantoprazole Sodium | 132 | $2,204 |
| Gabapentin | 119 | $2,060 |
| Levothyroxine Sodium | 199 | $1,957 |
Paid to pharmacies, not to this prescriber.
Other family in Plymouth Meeting
- Kathleen ScholzPittsburgh$397K
- Shannon FitzgeraldAllison Park$370K
- Stephanie HarshbargerCamp Hill$317K
- Whitney BowlesFort Washington$253K
- Kweilynn GreenePittsburgh$139K
- Jessica LindenbergerPittsburgh$131K
- Kami NestlerWilkes Barre$129K
- Bethany ThomasPhiladelphia$126K
- Margaret RosenzweigPittsburgh$89K
- Amanda GrippoDickson Cty$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.